Beacon Biomedical Teams with National Phlebotomy Providers Network To Launch a Nationwide Blood-Draw Service to Support BeScreened™-CRC
Read This Post on AZBio
Phoenix, Ariz. (March 19, 2019) –Beacon Biomedical Inc., a Phoenix-based diagnostic laboratory focused on developing and commercializing blood-based tests for earlier cancer detection, announced today they are teaming up with The National Phlebotomy Provider Network (NPPN), a professional 501c6 nonprofit organization for the collection and delivery of blood specimens, to provide Beacon with nationwide at-home and in-office blood-draw services in support of Beacon’s recently launched colorectal cancer screening test, BeScreened™-CRC.
Despite being one of the most preventable cancers, colorectal cancer is the 2nd leading cause of cancer deaths among men and women in the United States. In 2018 alone, there were an estimated 140,250 new cases of colorectal cancer and 50,630 deaths. While existing screening tests, such as fecal-based tests and colonoscopies, are extremely effective at finding colorectal cancer, they only work if they are used.
Recognizing that over 30 MM men and women in the U.S. are unable or unwilling to use these recommended screening tests, Beacon developed BeScreened™-CRC for healthcare providers as another “tool-in-the-toolbox” to help get these patients screened for colorectal cancer.
“While the reasons for not getting screened are varied, there is a direct link between the ease and convenience for getting tested and the level of screening compliance” said Donald Weber, CEO of Beacon Biomedical Inc. “Our goal is a simple one. We need to change a noncompliant patient’s “No” into a “Yes”. And, if the lack of having an easy and convenient way of getting screened is part of the problem, we believe our new, on-site phlebotomy services for BeScreened-CRC can help eliminate these barriers.”
As a blood-based test that is 94% accurate with no dietary or fasting restrictions, BeScreened-CRC is specifically intended for the noncompliant individual and purposely designed to help remove many of the barriers to colorectal cancer screening due to the test’s simplicity and ease of adoption.
“We are fully supportive of Beacon’s initiative to help improve colorectal cancer screening compliance by providing their patients with the convenience and comfort of an at-home or in-office blood draw.”, says Nathan Cron, CEO of The National Phlebotomy Provider Network. “Our primary mission is enabling access to world-class, life-saving diagnostic care, and we are thrilled to be partnering with Beacon in that effort.”
Patients and their physicians can request more information about BeScreened-CRC, the company’s new personalized blood-draw services and Beacon Biomedical by texting “CRC” to “555-888” or visiting www.beaconbiomedical.com.
About Beacon Biomedical Inc.
Beacon Biomedical Inc. is a CLIA accredited proteomic diagnostics laboratory focused on developing and commercializing blood-based tests for earlier cancer detection. The company’s lead product, BeScreened™-CRC, is a blood-based test for the earlier detection of colorectal cancer. Beacon’s product development pipeline includes early detection assays for breast, lung, prostate and ovarian cancers. For more information about Beacon visit, www.beaconbiomedical.com
About National Phlebotomy Provider Network
National Phlebotomy Provider Network (NPPN) is a professional association of organizations and individuals responsible for the collection, delivery, analysis, and diagnosis of blood specimens. NPPN is a 501c6 nonprofit organization whose members include phlebotomists, collection and delivery companies, laboratories, hospitals and other allied healthcare agencies. The mission of the NPPN is to facilitate access to cutting-edge, world-class diagnostic care and research in the pursuit of evidence-based medicine founded on the best diagnostic data available. For more information about NPPN visit, https://nppn.info
# # #